deferasirox has been researched along with Hepatitis C in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Della Pepa, R; Pane, F; Picardi, M; Pugliese, N | 1 |
| Barada, K; Khalife, M; Musallam, KM; Taher, AT | 1 |
| Brissot, P; Cappellini, MD; Deugnier, Y; Giannone, V; Griffel, L; Porter, JB; Ropert, M; Turlin, B; Zhang, Y | 1 |
1 trial(s) available for deferasirox and Hepatitis C
| Article | Year |
|---|---|
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Topics: Adolescent; Adult; Alanine Transaminase; Benzoates; beta-Thalassemia; Biomarkers; Biopsy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Female; Ferritins; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2011 |
2 other study(ies) available for deferasirox and Hepatitis C
| Article | Year |
|---|---|
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Myelodysplastic Syndromes | 2018 |
Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration?
Topics: Antiviral Agents; Benzoates; Deferasirox; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Male; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2009 |